With a low beta of 0.33 and a 3% 3-year dividend CAGR, this healthcare leader delivers meaningful downside protection while maintaining steady payout expansion in a cyclical sector.
The company operates two primary businesses: innovative medicines that address serious conditions in oncology, immunology, neuroscience, and cardiovascular health, and medical technology solutions spanning surgical tools, orthopaedics, vision care, and electrophysiology devices. Strong growth continues in high-value oncology and immunology treatments, fueled by recent regulatory approvals, strategic acquisitions, and a pipeline targeting multi-billion-dollar peak sales opportunities. These advances help offset pressures from biosimilar competition on mature products and ongoing litigation challenges.
We are reaffirming our position in this stock within the Best Healthcare Dividend Stocks Portfolio. Its combination of superior dividend safety, minimal returns risk, and resilient fundamentals aligns closely with our disciplined focus on quality income and capital preservation.
